Savaysa: Ph IIIb ENTRUST-AF PCI started

Daiichi began the open-label, international Phase IIIb ENTRUST-AF PCI trial to evaluate 30 and 60 mg oral Savaysa once daily vs. a vitamin K antagonist for 12 months in 1,500 patients. Patients will a...